List of Excipients in Branded Drug NEXTERONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Company	NEXTERONE	amiodarone hydrochloride	43066-150	ANHYDROUS CITRIC ACID
Baxter Healthcare Company	NEXTERONE	amiodarone hydrochloride	43066-150	ANHYDROUS DEXTROSE
Baxter Healthcare Company	NEXTERONE	amiodarone hydrochloride	43066-150	BETADEX SULFOBUTYL ETHER SODIUM
Baxter Healthcare Company	NEXTERONE	amiodarone hydrochloride	43066-150	HYDROCHLORIC ACID

NEXTERONE Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

NEXTERONE is a ready-to-use intravenous amiodarone hydrochloride product that differentiates itself through formulation design rather than active-ingredient exclusivity. Its core excipient strategy uses sulfobutyl ether beta-cyclodextrin sodium, marketed as Captisol, to solubilize amiodarone while avoiding polysorbate 80 and benzyl alcohol. The commercial opportunity is concentrated in hospital workflow, medication safety, premixed delivery, supply reliability, and lifecycle extensions rather than protection of amiodarone itself.

What is NEXTERONE and how does its formulation differ?

NEXTERONE is an intravenous amiodarone hydrochloride injection supplied in ready-to-use containers. The product is indicated for initiation and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia when other therapies are ineffective or unsuitable. It is marketed by Baxter Healthcare Corporation under NDA 022275. The product was approved in the United States in 2009. [1]

The principal formulation distinction is the use of sulfobutyl ether beta-cyclodextrin sodium, or SBECD, as a solubilizing excipient. Conventional injectable amiodarone products commonly use surfactants and preservatives, including polysorbate 80 and benzyl alcohol. NEXTERONE uses SBECD to form an inclusion complex with amiodarone and permit aqueous intravenous delivery.

Attribute	NEXTERONE	Conventional amiodarone injection
Active ingredient	Amiodarone hydrochloride	Amiodarone hydrochloride
Delivery	Ready-to-use IV solution	Often requires dilution or preparation
Primary solubilizer	SBECD, Captisol	Commonly polysorbate 80 and benzyl alcohol
Diluent	Dextrose 5% in water	Often D5W before administration
Preservative strategy	No benzyl alcohol listed in the NEXTERONE formulation	Product-dependent
Surfactant strategy	No polysorbate 80 listed	Product-dependent
Commercial differentiation	Premix, excipient profile, workflow	Lower-cost active-ingredient supply

The product is available in at least two core presentations: 150 mg in 100 mL and 360 mg in 200 mL. The labeled formulation contains dextrose, SBECD, water for injection, and pH-adjusting agents. [1,2]

What excipients protect the commercial position of NEXTERONE?

The most important excipient is SBECD. Amiodarone has poor aqueous solubility, creating a formulation challenge for intravenous administration. SBECD improves apparent solubility without relying on the surfactant-preservative combination used in many conventional products.

SBECD and Captisol

SBECD is a modified beta-cyclodextrin designed for parenteral drug solubilization. Ligand Pharmaceuticals commercializes the Captisol platform and licenses it for use in pharmaceutical products. [3]

Its strategic value in NEXTERONE includes:

• Solubilization of amiodarone in an aqueous IV vehicle.
• Avoidance of polysorbate 80.
• Avoidance of benzyl alcohol.
• Compatibility with a ready-to-use premixed presentation.
• Potentially simpler administration in intensive-care and emergency settings.
• A formulation platform that could be adapted to other poorly soluble emergency medicines.

The excipient is not merely an inactive substitute. It determines whether amiodarone can be supplied as a stable, premixed IV product without the same surfactant and preservative system found in older products.

Dextrose 5% in water

NEXTERONE is supplied in D5W. The use of a standard hospital-compatible vehicle supports direct administration and reduces compounding steps. It also limits the need for pharmacy dilution before infusion.

D5W creates some formulation and commercial constraints. Hospitals may need to account for glucose administration in patients with diabetes, critical illness, or fluid-management restrictions. A future low-volume, higher-concentration presentation could address some of these use cases, but it would require new stability, container, administration, and labeling work.

Excipients excluded from the product

NEXTERONE’s label identifies a formulation that does not use benzyl alcohol or polysorbate 80. This exclusion can support differentiation in neonatal, pediatric, critical-care, and preservative-sensitive settings, although the product remains an amiodarone formulation with substantial cardiovascular and organ-toxicity warnings. [1]

The commercial message should focus on formulation composition and workflow. It should not imply that the product eliminates the clinical risks associated with intravenous amiodarone.

What formulations are protected by NEXTERONE’s excipient strategy?

NEXTERONE’s defensible product space is likely concentrated in the combination of:

1. Amiodarone hydrochloride.
2. SBECD as the solubilizer.
3. Dextrose-based aqueous IV delivery.
4. Specific concentration ranges.
5. Ready-to-use container presentations.
6. Stability and storage characteristics.
7. Manufacturing and filling processes.

The active molecule, amiodarone, is long off patent. Any meaningful formulation protection would therefore depend on claim scope around excipient ratios, concentrations, pH, stability, packaging, manufacturing, or use.

A formulation patent can be commercially valuable even when it does not prevent all amiodarone injections. Its practical value depends on whether a competing manufacturer can develop a different formulation, use a different solubilizer, or obtain approval through an alternative regulatory pathway.

How strong is the patent estate for NEXTERONE?

The patent estate should be viewed as narrower and more design-aroundable than a new chemical entity estate.

Protection category	Strategic value	Likely vulnerability
Amiodarone composition-of-matter protection	Low	Expired or unavailable
SBECD-amiodarone formulation	Moderate	Alternative cyclodextrins or excipients
Premixed IV container	Moderate	Alternative concentrations and bag systems
Stability claims	Moderate	Different packaging or storage conditions
Manufacturing process	Low to moderate	Process substitution
Method-of-use claims	Moderate	Existing clinical use is well established
Captisol platform rights	Important to formulation access	Licensing and supply dependence

The central risk is a competitor that uses a different solubilizer or a different concentration and avoids formulation claims. SBECD itself is commercially established in approved parenteral products, which reduces regulatory uncertainty but can increase dependence on the Captisol supply chain.

No patent number, expiration date, or current claim set should be treated as controlling without reviewing the current USPTO file history, FDA Orange Book record, and relevant assignment data. The FDA label does not itself establish the full patent position. [1,4]

What is the FDA regulatory status and Orange Book position?

NEXTERONE is an FDA-approved prescription injectable drug under NDA 022275. It is a small-molecule product, not a biologic. Biosimilar regulation therefore does not apply. Competing products would generally proceed through an ANDA, a 505(b)(2) application, or an alternative NDA strategy depending on formulation, labeling, and reliance on the reference product.

The relevant regulatory questions are:

• Whether NEXTERONE is the reference listed drug for a proposed ANDA.
• Whether the proposed generic has the same active ingredient, dosage form, strength, route, and labeling.
• Whether the formulation differences affect bioequivalence or clinical safety.
• Whether listed patents or regulatory exclusivity remain relevant.
• Whether a 505(b)(2) applicant can rely on existing amiodarone safety and efficacy findings while using a different excipient system.

The original three-year new-drug exclusivity period associated with the approval would not provide a current commercial barrier. The active ingredient is also not protected by new chemical entity exclusivity. Current market protection therefore depends principally on formulation, regulatory complexity, manufacturing quality, procurement contracts, and brand preference.

The Orange Book should be used to confirm listed patents, patent-use codes, reference-listed-drug status, and therapeutic-equivalence information. [4]

When does NEXTERONE lose exclusivity?

NEXTERONE’s key exclusivity periods have already expired or are no longer the primary commercial barrier.

Exclusivity or protection	NEXTERONE implication
New chemical entity exclusivity	Not available for long-established amiodarone
Three-year new clinical investigation exclusivity	Original approval-related period has expired
Orphan-drug exclusivity	Not the principal protection for NEXTERONE
Formulation patents	Potentially relevant, depending on claims and expiration
Trade dress and trademarks	Commercial protection only
Manufacturing know-how	May remain valuable but is not regulatory exclusivity

The most realistic generic-entry date is therefore governed by the expiration or successful challenge of any enforceable formulation patents and by FDA approval timing, not by the amiodarone molecule.

Which companies are challenging NEXTERONE?

Generic amiodarone injection competition already exists in the United States. Manufacturers such as Hikma, Fresenius Kabi, Sandoz, and other injectable-drug suppliers have marketed amiodarone injection products or related presentations, although product availability, strengths, labels, and current marketing status vary by manufacturer. FDA’s Drugs@FDA and Orange Book databases are the appropriate sources for current product and therapeutic-equivalence status. [4,5]

The competitive field divides into three groups:

Conventional amiodarone injection manufacturers

These companies compete primarily on acquisition cost, supply reliability, and hospital contracting. They may use different excipient systems and require different preparation procedures.

Premix and ready-to-use competitors

A competitor that offers premixed amiodarone in D5W can attack NEXTERONE’s principal workflow advantage. The most valuable competitive features are ready-to-administer packaging, shelf life, room-temperature storage, and standardized concentrations.

Formulation-platform competitors

Companies with alternative solubilization technologies could avoid dependence on Captisol. Candidate approaches may include other cyclodextrins, cosolvent systems, lipid-based vehicles, or proprietary complexation technologies. Each approach would require a separate assessment of IV tolerability, precipitation risk, infusion compatibility, and container stability.

What generic entry risks exist for NEXTERONE?

Generic entry risk is high for the active ingredient and moderate for the specific premixed formulation.

Paragraph IV challenges

A Paragraph IV applicant could challenge listed formulation patents by asserting that the patents are invalid, unenforceable, or not infringed. The commercial strength of such a challenge would depend on:

• Whether the patent claims require SBECD specifically.
• Whether the claims cover concentration and excipient ratios.
• Whether the reference product’s formulation is adequately disclosed.
• Whether prior art teaches SBECD use with amiodarone.
• Whether the applicant can design around the claims.
• Whether the patent is listed with a valid use code or formulation description.

A competitor using a different solubilizer may avoid a Paragraph IV dispute altogether and pursue approval through a different formulation strategy.

Substitution risk

Hospitals may substitute a lower-cost amiodarone injection if pharmacy staff can prepare the product safely and supply remains reliable. NEXTERONE’s defense is strongest where preparation time, medication-error risk, and emergency availability have measurable operational value.

Supply-chain risk

Captisol dependence creates a potential single-platform vulnerability. A shortage of SBECD, a manufacturing interruption, or a price increase could affect the product’s gross margin and availability. Dual sourcing of critical excipients is difficult if the formulation relies on a proprietary grade.

What patent litigation affects NEXTERONE?

The principal litigation risk is formulation patent litigation involving SBECD-amiodarone compositions, ready-to-use presentations, or manufacturing processes. No specific active Paragraph IV settlement or current litigation outcome is established in the FDA product materials cited here. Product-specific litigation should be checked against PACER, USPTO assignment and file-history records, FDA Orange Book updates, and public company disclosures before relying on it for launch planning.

Potential litigation scenarios include:

1. A Paragraph IV challenge to a listed formulation patent.
2. An infringement action against a ready-to-use competitor.
3. A trade-secret dispute involving compounding or filling processes.
4. A license dispute involving Captisol or SBECD supply.
5. Antitrust scrutiny if formulation rights are used to restrict alternative premix suppliers.

What commercial opportunities exist for NEXTERONE excipients?

Hospital premix expansion

The strongest opportunity is expansion of ready-to-use IV presentations. Hospitals continue to seek products that reduce pharmacy preparation, improve emergency access, and standardize dosing.

Commercially relevant extensions include:

• Smaller-volume bags for fluid-restricted patients.
• Additional standardized concentrations.
• Syringe presentations for emergency departments and transport services.
• Longer room-temperature stability.
• Improved overwrap and light-protection systems.
• Presentations compatible with automated dispensing and smart pumps.

Contract manufacturing and private label

A manufacturer with access to SBECD formulation expertise could offer contract development and manufacturing services to hospital systems, specialty injectable companies, and regional pharmaceutical suppliers.

The opportunity is strongest where the partner lacks:

• Sterile formulation expertise.
• Cyclodextrin development capability.
• Ready-to-use bag filling.
• Stability data.
• Injectable regulatory experience.

Platform licensing

The Captisol-based formulation approach may be adapted to other poorly soluble injectable drugs. A licensing strategy could include:

• SBECD formulation development.
• Analytical methods for complexation and free-drug measurement.
• Container-closure compatibility.
• Freeze-thaw and agitation studies.
• Sterile filling and scale-up support.
• Regulatory documentation for 505(b)(2) products.

Geographic expansion

The premix value proposition is most relevant in markets with centralized hospital pharmacies, high emergency-care utilization, and strong demand for injectable supply reliability. Geographic expansion would require review of:

• Local excipient and preservative requirements.
• Container and labeling rules.
• Reference-product status.
• Stability zones.
• Hospital procurement structures.
• Captisol licensing rights by territory.

How does NEXTERONE compare with conventional amiodarone injection?

NEXTERONE is commercially stronger on workflow and formulation differentiation, while conventional amiodarone injection is generally stronger on price and supplier breadth.

Commercial factor	NEXTERONE	Conventional injection
Acquisition price	Typically higher	Typically lower
Pharmacy preparation	Minimal or none	May require dilution
Excipient differentiation	Strong	Product-specific
Supply flexibility	Dependent on premix and SBECD supply	More supplier options
Emergency-use convenience	High	Variable
Generic substitution pressure	Moderate	High
Lifecycle extension potential	High through packaging and concentrations	Limited unless reformulated

NEXTERONE should be positioned as a medication-delivery product, not simply as another amiodarone source. The economic case depends on avoided preparation, reduced inventory complexity, lower error exposure, and dependable emergency availability.

What manufacturing and IP barriers matter most?

The major barriers are technical execution and sterile manufacturing rather than the active ingredient.

Key barriers include:

• Maintaining amiodarone-SBECD complexation during scale-up.
• Preventing precipitation after dilution or temperature change.
• Controlling pH and osmolality.
• Demonstrating container compatibility.
• Managing adsorption to bags, tubing, and administration sets.
• Establishing extractables and leachables profiles.
• Achieving terminal sterilization or validated aseptic processing.
• Preserving stability through shipping and storage.
• Securing qualified SBECD supply.
• Supporting a complete injectable regulatory package.

These barriers create a moderate entry threshold. They can delay competitors, but they do not guarantee durable exclusivity if alternative formulations are technically feasible.

Key Takeaways

• NEXTERONE’s commercial identity is built on SBECD-enabled solubilization, premixed D5W delivery, and avoidance of polysorbate 80 and benzyl alcohol.
• Amiodarone itself provides little or no meaningful current patent protection.
• The most important IP questions concern formulation claims, concentration ranges, container systems, and manufacturing processes.
• Three-year approval-related exclusivity is historical, not a current barrier.
• Biosimilar risk does not apply because NEXTERONE is a small-molecule drug.
• Generic entry risk is high for conventional amiodarone injection and moderate for the specific ready-to-use formulation.
• The best commercial opportunities are smaller-volume premixes, emergency syringes, private-label manufacturing, Captisol formulation licensing, and geographic expansion.
• Captisol supply and formulation know-how are strategic dependencies.
• NEXTERONE’s strongest defense is hospital workflow value, not molecule exclusivity.

FAQs

Is Captisol essential to NEXTERONE?

SBECD is central to the labeled NEXTERONE formulation, but a competitor could theoretically use another solubilization system if it demonstrated adequate safety, stability, and regulatory performance.

Can a generic amiodarone injection substitute for NEXTERONE?

Substitution depends on FDA therapeutic-equivalence status, product labeling, concentration, dosage form, and state pharmacy rules. A conventional amiodarone injection may not replicate the ready-to-use characteristics of NEXTERONE.

Is NEXTERONE preservative-free?

The labeled formulation does not list benzyl alcohol as an ingredient. Product-specific labeling should be reviewed for each presentation.

What is the main commercial weakness of NEXTERONE?

The principal weakness is price pressure from lower-cost amiodarone injections and the possibility that competitors reproduce the premix workflow using a different excipient system.

Could SBECD create a new pediatric amiodarone opportunity?

A pediatric opportunity is technically plausible, particularly for low-volume or preservative-avoiding presentations. It would require dedicated dosing, safety, stability, administration, and regulatory development rather than simple repackaging.

References

1. U.S. Food and Drug Administration. (n.d.). NEXTERONE (amiodarone hydrochloride) injection prescribing information. Baxter Healthcare Corporation.

2. DailyMed. (n.d.). NEXTERONE- amiodarone hydrochloride injection, solution. National Library of Medicine.

3. Ligand Pharmaceuticals Incorporated. (n.d.). Captisol sulfobutyl ether beta-cyclodextrin pharmaceutical excipient platform. https://www.ligand.com

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/